SIGA Technologies (SIGA) said Thursday its antiviral treatment TEPOXX has received regulatory approval in Japan for the treatment of smallpox, mpox, cowpox, and complications from smallpox vaccinations in patients weighing at least 13 kilograms (28.7 pounds).
The drug, also called tecovirimat and marketed as TPOXX in the US, received approval from Japan's Pharmaceuticals and Medical Devices Agency, and will be distributed in partnership with Japan Biotechno Pharma, the company said.
SIGA said it has already delivered an order of TEPOXX to help build Japan's strategic stockpile.
Shares of SIGA were up 6% in recent Thursday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.